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Abstract
A rapid, cost-effective diagnostic test for the detection of acute HIV-1 infection is highly de-
sired. Isothermal amplification techniques, such as reverse-transcription loop-mediated iso-
thermal amplification (RT-LAMP), exhibit characteristics that are ideal for the development
of a rapid nucleic acid amplification test (NAAT) because they are quick, easy to perform
and do not require complex, dedicated equipment and laboratory space. In this study, we
assessed the ability of the HIV-1 RT-LAMP assay to detect acute HIV infection as compared
to a representative rapid antibody test and several FDA-approved laboratory-based assays.
The HIV-1 RT-LAMP assay detected seroconverting individuals one to three weeks earlier
than a rapid HIV antibody test and up to two weeks earlier than a lab-based antigen/anti-
body (Ag/Ab) combo enzyme immunoassay (EIA). RT-LAMP was not as sensitive as a lab-
based qualitative RNA assay, which could be attributed to the significantly smaller nucleic
acid input volume. To our knowledge, this is the first demonstration of detecting acute HIV
infection using the RT-LAMP assay. The availability of a rapid NAAT, such as the HIV-1 RT-
LAMP assay, at the point of care (POC) or in laboratories that do not have access to large
platform NAAT could increase the percentage of individuals who receive an acute HIV infec-
tion status or confirmation of their HIV status, while immediately linking them to counseling
and medical care. In addition, early knowledge of HIV status could lead to reduced high-risk
behavior at a time when individuals are at a higher risk for transmitting the virus.
Introduction
Routine diagnostic testing is imperative for the early detection and treatment of HIV infection.
Because individuals are at higher risk for transmitting the virus during early or acute infection,
accurate and timely diagnosis may reduce the transmission of HIV when the individual is most
infectious [1]. Early detection of HIV has been shown to lead to reduced high-risk behavior
and to connect individuals to treatment earlier, which can reduce the risk of virus transmission
[2, 3]. In 2006, an MMWR was published that advocated routine, voluntary testing of adults,
adolescents, and pregnant women aged 13–64 years in health-care settings as normal practice
[2]. Although there are currently a large number of FDA-approved HIV diagnostic tests with
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high sensitivities and specificities available, there were still 1.1 million people in the U.S. living
with HIV at the end of 2011, of which, 15.8% remained undiagnosed or were unaware of their
infection status [4]. Point-of-care (POC) testing has increased the number of individuals who
are screened for HIV and receive their HIV test results [5]. In the U.S., examples of POC set-
tings may include, but are not limited to, clinics, mobile testing units, jails, and
emergency rooms.
For laboratory settings, a revised HIV testing algorithm has been published to improve
upon the accurate detection of acute HIV-1 infection, as well as HIV-2 [6]. In this algorithm,
specimens are screened with a sensitive HIV-1/2 immunoassay, preferably a fourth-generation
antigen/antibody assay, followed by an HIV-1/2 differentiation assay. Specimens that are non-
reactive are considered negative. Specimens that have concordant reactivity on the screening
and supplemental test are considered positive for HIV-1/2 antibodies; however, in the case of
discordant immunoassay results, HIV-1 nucleic acid amplification testing (NAAT) is recom-
mended. NAAT is highly sensitive, virus specific, and allows for detection of infection approxi-
mately two weeks earlier than most antibody-based tests [5, 6].
To date, there are no definitive guidelines for HIV testing at the POC. Rapid tests have facil-
itated HIV testing at the POC because they can be completed in a short period of time (typical-
ly less than 30 minutes) and require minimal technical expertise. Currently, there are a number
of rapid antibody tests available that are FDA-approved; however, they are not as sensitive for
detection of early HIV infection as most laboratory based assays and will remain negative dur-
ing the period post-infection, but pre-seroconversion [7]. The availability of a rapid NAAT for
use at the POC could increase the ability to detect acute infection. The Aptima HIV-1 Assay
(Hologic Inc., San Diego, CA) is currently the only FDA-approved diagnostic NAAT, but its
use is not feasible for the POC due to the high cost per test, dedicated equipment requirements,
and the need for trained technical staff. Ideally, a rapid NAAT should be completed in a short
time frame with a few simple steps, be easy to interpret, and require no or minimal equipment.
In addition, the rapid NAAT must exhibit a high degree of sensitivity and specificity. Isother-
mal amplification techniques are attractive for the development of a rapid NAAT because they
do not require thermal cycling and, therefore, the reaction can be run in a simple heat block,
water bath, or other portable heating device [8]. One such isothermal technique, loop-mediated
isothermal amplification (LAMP), has been developed for the detection of DNA [9] and RNA
(reverse-transcription, loop-mediated isothermal amplification or RT-LAMP) [10–13].
The LAMP technique has several characteristics that are appealing for the development of a
rapid NAAT. The amplification method is highly specific because it requires six primers that
recognize eight different sequences in the same target region. The method is less sensitive to bi-
ological inhibitors than PCR, which allows for amplification directly from biological samples,
such as whole blood, plasma and oral fluid, without the need for extraction of nucleic acid [14–
18]. Amplified material can be detected within 15–60 minutes when incubated at a constant
temperature (60–65°C) and immediate visual detection is possible due to the large amount of
DNA generated from each reaction [19]. In addition, several groups have incorporated fluores-
cent detection methods into the LAMP assay for real-time or immediate naked-eye detection
[17] [19–22]. We have demonstrated previously the development of an HIV-1 RT-LAMP
assay that incorporates a sequence-specific detection method and allows for the simultaneous
detection of both RNA and DNA in a single reaction tube [17].
In this study, we evaluated the ability of the HIV-1 RT-LAMP assay to detect acute HIV in-
fection as compared to a representative rapid antibody test and several laboratory-based assays.
Using two primer sets directed against highly conserved regions within the reverse transcrip-
tase (RT) and integrase (INT) genes and well-characterized seroconversion panels from recent
seroconverters, we demonstrated that the HIV-1 RT-LAMP assay was able to detect samples
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from acutely infected individuals up to 24 days prior to a representative rapid antibody test.
The HIV-1 RT-LAMP assay, used in conjunction with current rapid antibody tests, has the po-
tential to increase the number of individuals who receive an accurate and timely HIV result at
the POC or in select laboratory settings, where cost and time restraints prohibit the use of stan-
dard NAAT platforms.
Materials and Methods
RT-LAMP Primers and Quenchers
HIV-1 RT-LAMP primers specific for the RT gene region have previously been described [8].
The RT primers recognize target sequences within the genome location 2900–3118, relative to
the HXB2 reference strain. In this study, a truncated version of the RT quencher probe with a
3’ BHQ-1 label (AAACAATGAGACACC-BHQ1) was designed to be added directly into the
reaction mix as opposed to adding post-reaction, as in previous studies [8, 17]. This eliminates
the need to open the reaction tubes after amplification and reduces the risk of amplicons being
released and contaminating the work environment. An additional HIV-1 primer set was de-
signed in a highly conserved region of the INT gene, using PrimerExplorer V3 software avail-
able on the Eiken Chemical Co. Ltd. (Japan) website (http://primerexplorer.jp/e/). A region
within the integrase gene was selected for primer design due to the high degree of sequence
conservation within subtype B and across the group M subtypes, as summarized in the HIV Se-
quence Compendium (http://www.hiv.lanl.gov/). The HIV-1 HXB2 sequence (GenBank acces-
sion number AF033819) was used as the reference for generating the primers. The sequences
of the INT primers and quencher probe are listed in Table 1. All primers were synthesized in-
house and the FIP and BIP primers were HPLC purified.
HIV-1 DNA and RNA Linearity Panels
An HIV-1 DNA linearity panel was created using the human monocytic cell line OM-10.1
[23], which contains a single integrated HIV-1 provirus per cell. DNA was extracted using a
QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA), as previously described [17]. A panel
was created ranging from 105 to 102 copies/ml using serial, tenfold dilutions in diethylpyrocar-
bonate (DEPC)-treated water (Invitrogen, Carlsbad, CA). A negative DNA control was gener-
ated by extracting DNA from peripheral blood mononuclear cells (PBMCs) infected with an
HIV-2 isolate, NIH-Z (Advanced Biotechnologies, Inc., Columbia, MD). Due to the genetic di-
versity between HIV-1 and HIV-2 and the specificity of the RT-LAMP assay, HIV-1 primers
do not amplify HIV-2 targets.
An HIV-1 RNA linearity panel was created using the supernatant from 8E5 cells (ATCC,
Manassas, VA), which contain a single defective proviral genome of HIV-1 per cell, but still
Table 1. INT Primer and Quencher Probe Sequences.
Primer Name HXB2 Location Sequence (5’! 3’)
F3 4901–4920 GGTTTATTACAGGGACAGCA
B3 5070–5087 ATCCTGTCTACTTGCCAC
LoopF 4943–4962 CTTTCCAGAGAAGCTTTGCT
LoopB-HEX 5021–5042 HEX-AGCAAAGATCATTAGGGATTAT
FIP 4963–4986, 4923–4942 CTTGTATTACTACTGCCCCTTCACGATCCACTTTGGAAAGGACC
BIP 4994–5018, 5051–5069 TGACATAAAAGTAGTGCCAAGAAGATTTTACAATCATCACCTGCCATC
LoopB-Q 5021–5034 TAATGATCTTTGCT-BHQ1
doi:10.1371/journal.pone.0126609.t001
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express virus in the supernatant. The viral load of the cell supernatant was determined using
the Roche COBAS AmpliPrep / COBAS TaqMan HIV-1 Test V2.0 (Roche Diagnostics, India-
napolis, IN) and the supernatant was spiked into HIV-1 seronegative human plasma. Serial di-
lutions were made in plasma to create a panel that ranged from 106 to 103 RNA copies/ ml.
RNA was extracted from the panel using a QIAamp Viral RNAMini Kit (QIAGEN, Valencia,
CA). Positive and negative controls included RNA extracted from HIV-1 BaL purified virus
and HIV-2 NIH-Z purified virus (Advanced Biotechnologies Inc., Columbia, MD), respective-
ly. Aliquots of both linearity panels were made and stored at -80°C until use.
HIV-1 Seroconversion Panels
Serial plasma specimens were collected from 12 US donors who became HIV-1 infected during
the collection period. The seroconversion panels were obtained from SeraCare Life Sciences
(n = 7) (Gaithersburg, MD) and ZeptoMetrix Corp. (n = 5) (Buffalo, NY) [24, 25]. The Multi-
spot HIV-1/HIV-2 Rapid Test (Bio-Rad, Redmond, CA), GS HIV-1 Western blot (Bio-Rad),
third-generation GS HIV-1/HIV-2 Plus O EIA (Bio-Rad), fourth-generation GS HIV Combo
Ag/Ab EIA (Bio-Rad), and APTIMA HIV-1 Qualitative Assay (Hologic Inc., San Diego, CA)
test results were compared with the results from the RT-LAMP assay. These test results are rep-
resented as rapid Ab, WB, Ab EIA, Ag + Ab EIA and qualitative RNA, respectively. For the Ser-
aCare panels, all HIV test results were supplied by the manufacturer, with the exception of the
Multispot and the APTIMA, which were performed in-house according to the package inserts.
Viral loads were supplied by the manufacturer and were determined using the COBAS Ampli-
Prep / COBAS TaqMan HIV-1 Test V2.0 (Roche Diagnostics, Indianapolis, IN), except for
panels PRB970 and PRB946, which were determined by the COBAS AmpliPrep / COBAS Taq-
Man HIV-1 Test V1.0 (Roche Diagnostics, Indianapolis, IN) and the Amplicor HIV-1 Monitor
Test (Roche Diagnostics, Indianapolis, IN), respectively. The lower limit of detection of the
COBAS TaqMan HIV-1 Test V2.0, V1.0, and Amplicor HIV-1 Monitor Test is 20, 40, and 50
copies/ mL, respectively. For the Zeptometrix panels, all HIV testing was performed in-house
according to the package inserts. The viral loads for each sample were determined by the
COBAS AmpliPrep / COBAS TaqMan HIV-1 Test V2.0. For RT-LAMP testing, RNA was ex-
tracted from the panels using a QIAamp Viral RNAMini Kit (Qiagen, Valencia, CA).
RT-LAMP Reaction
The RT-LAMP reaction was performed as described previously, with a few modifications [17].
Briefly, the RT-LAMP reaction mix (25 μL volume total) contained a final concentration of
0.2 μM each of F3 and B3 primers, 1.6 μM each of FIP and BIP primers (both HPLC purified,
as recommended [26]), 0.8 μM each of LoopF and LoopB primers (a 5’ HEX label was added to
LoopF for RT and LoopB for INT), 0.8M Betaine (Sigma-Aldrich, St. Louis, MO), 8 mM
MgSO4, 1.4 mM dNTPs (Roche Applied Science, Indianapolis, IN), 1X Isothermal Amplifica-
tion Buffer (New England Biolabs, Ipswich, MA), 16U Bst 2.0 WarmStart DNA Polymerase
(New England Biolabs) and 2U AMV Reverse Transcriptase (Life Technologies, Carlsbad,
CA). The addition of a reverse transcriptase enzyme allows the amplification of both DNA and
RNA simultaneously in the same reaction tube. In addition, a 3’ BHQ1-labeled quencher probe
was added into the reaction at a final concentration of 0.8μM. To the reaction mixture, 10 μL
of extracted DNA or RNA was added. The reaction mixture was heated at 60°C for 60 minutes,
using a GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA), then held at 80°C
for 2 minutes to terminate the reaction. For the purposes of the current evaluation, each speci-
men was tested in duplicate with each primer set. In addition to positive and negative controls,
a reagent (no template) control was included in every run to check for reagent contamination.
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The presence of amplified product was determined visually by observing fluorescence in the re-
action tubes using the UV lamp from a GelDoc XR+ Imaging System (BioRad Laboratories,
Hercules, CA).
Results
HIV-1 INT RT-LAMP Sensitivity
The sensitivity of the HIV-1 RT-LAMP assay using the RT primers has been previously de-
scribed [8]. The sensitivity of the assay for both DNA and RNA using the INT primers was
similar to the reported sensitivity for the RT primers. A representative experiment demonstrat-
ing amplification of HIV-1 DNA and RNA linearity panels is shown in Fig 1. The limit of de-
tection for DNA was 102 copies/ mL and 105–104 RNA copies/ mL, depending on the
experiment. No amplification was observed in the negative control or the reagent control tube.
Evaluation of RT-LAMP Assay with Acute HIV-1 Clinical Samples
To determine the ability of the RT-LAMP assay to detect samples from acute HIV-1 infection,
seroconversion panels were tested. For the SeraCare samples (n = 7), only one of the panels be-
came reactive during the sample collection period by the rapid Ab test. This particular sample
became rapid Ab reactive 14 days after the first detectable viral load and the first qualitative
RNA positive (Table 2). In contrast, all of the SeraCare panels were reactive by the HIV-1
RT-LAMP assay between 0 and 2 days (median = 0) after the first detectable viral load and
qualitative RNA positive. For most panels, both the RT and INT primers detected samples
from the same time point; however, in select cases, one primer set detected a sample prior to
the other. Based on the viral load data from the panel, the RT primer set detected all of the
Fig 1. HIV-1 INT RT-LAMP Sensitivity. The RT-LAMP reaction tubes were observed under UV light. Representative tubes for amplification of DNA and
RNA are shown.
doi:10.1371/journal.pone.0126609.g001
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SeraCare samples in the expected sensitivity range of the assay (> 104 RNA copies/ mL) and
the INT primer set detected 6 out of 7 of the panels in the expected sensitivity range. In com-
parison to the laboratory-based tests, the RT-LAMP assay detected members in all seroconver-
sion panels prior to the Ab EIA, and 0 to 7 days (median = 3.5) prior to the Ag + Ab EIA. None
of the seroconversion panel members became WB positive during the sample collection period.
For the ZeptoMetrix panels (n = 5), the rapid Ab test detected panel members 7 to 29 days
(median = 19) post first detectable viral load and the first qualitative RNA positive (Table 3). In
contrast, the RT-LAMP assay detected panel members within 0 to 5 days (median = 5) post
first detectable viral load and qualitative RNA positive, which was 7 to 24 days (median = 15)
earlier than the rapid Ab test. Overall, similar reactivity was observed between the RT and the
INT primers for RT-LAMP with this panel. In comparison to the laboratory-based tests, the
RT-LAMP assay detected panel members anywhere from 2 to 14 days (median = 9) prior to
the Ab EIA and 0 to 14 days (median = 2) prior to the Ag + Ab EIA. The RT-LAMP assay was
able to detect samples 9 to 29 days (median = 22) before the WB assay. Overall, the RT-LAMP
Table 2. Evaluation of RT-LAMP Assay with SeraCare Seroconversion Panels.
Panel ID Days Since 1st VL Viral Load Qual RNA RT RT-LAMP INT RT-LAMP Ag+Ab EIA Ab EIA WB Rapid Ab
PRB973-01 0 1.8x103 + - - - - - -
PRB973-02 2 1.7x104 + + + - - - -
PRB973-03 7 1.7x105 + + + + - - -
PRB973-04 11 1.5x106 + + + + + IND -
PRB974-01 -7 BLD - - - - - - -
PRB974-02 0 8.6x103 + + + - - - -
PRB974-03 2 8.3x104 + + + + - - -
PRB974-04 9 9.6x105 + + + + - - -
PRB975-01 -7 BLD - - - - - - -
PRB975-02 -5 BLD - - - - - - -
PRB975-03 0 1.4x102 + - - - - - -
PRB975-04 2 2.1x103 + + + - - - -
PRB975-05 7 1.8x106 + + + + - - -
PRB976-01 0 1.2x104 + +/- + - - - -
PRB976-02 2 2.1x104 + + + - - - -
PRB976-03 7 6.3x105 + + + + - - -
PRB976-04 9 1.9x106 + + + + - - -
PRB977-01 0 1.9x102 + - - - - - -
PRB977-02 2 3.5x103 + - +/- - - - -
PRB977-03 13 1.6x106 + + + + - - -
PRB977-04 15 1.0x107 + + + + + - -
PRB970-01 0 1.6x105 + + + + - - -
PRB970-02 7 >1x107 + + + + - - -
PRB970-03 10 2.8x106 + + + + + - -
PRB970-04 14 6.5x104 + + + + + IND +
PRB946-01 -4 BLD - - - ND - - -
PRB946-02 0 3.0x104 + +/- - ND - - -
PRB946-03 3 7.0x105 + + + ND - - -
PRB946-04 7 >8x105 + + + ND - - -
+, reactive test result; -, non-reactive test result; +/-, reactive in 1 of 2 replicates; IND, indeterminate; ND, no data; *, first detectable viral load.
doi:10.1371/journal.pone.0126609.t002
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assay detected all of the Zeptometrix panel members within our expected viral load sensitivity
range (104 RNA copies/ mL). A summary of the HIV-1 test results for these panels, in rela-
tion to the first rapid Ab reactive test result is shown in Fig 2. The SeraCare panels were not in-
cluded in the timeline because of the short follow-up time and the fact that only one subject
became rapid Ab test reactive during the sample collection period.
Discussion
The primary goal of this study was to demonstrate the utility of the HIV-1 RT-LAMP assay for
detection of acute HIV-1 infection. To our knowledge, this is the first demonstration of acute
Table 3. Evaluation of RT-LAMP Assay with Zeptometrix Seroconversion Panels.
Panel ID Days Since 1st VL Viral Load Qual RNA RT RT-LAMP INT RT-LAMP Ag+Ab EIA Ab EIA WB Rapid Ab
6240–6 0 2.43x101 + - - - - - -
6240–7 5 2.41 x 104 + + + - - - -
6240–8 7 8.42 x 104 + + + + - IND -
6240–9 12 7.28 x 105 + + + + - IND -
6240–10 14 1.45 x 106 + + + + + IND -
6240–12 29 5.07 x 104 + + + + + + +
12007–3 -63 BLD - - - - - - -
12007–4 0 1.80 x 105 + + + + - - -
12007–5 2 1.29 x 105 + + + + + IND -
12007–6 7 4.89 x 104 + + + + + IND +
12007–7 9 4.91 x 104 + + + + + + +
12008–6 -5 BLD - - - - - ND -
12008–7 0 9.99 x 102 + +/- - - - ND -
12008–8 2 3.20 x 104 + + + - - - -
12008–9 7 4.70 x 106 + + + + - - -
12008–10 12 > 1.0 x 107 + + + + + - -
12008–11 14 > 1.0 x 107 + + + + + + -
12008–12 19 1.09 x 105 + + + + + + +
9079–8 0 2.08 x 101 + - - - - ND -
9079–9 5 9.60 x 104 + + + + - - -
9079–10 7 3.40 x 105 + + + + - - -
9079–11 12 8.32 x 105 + + + + + - -
9079–12 14 1.33 x 106 + + + + + IND -
9079–13 20 1.56 x 105 + + + + + IND +
9079–14 22 3.0 x 104 + + +/- + + IND +
9079–15 27 7.21 x 103 + + - + + + +
9032–6 0 1.62 x 103 + - - - - - -
9032–7 5 4.49 x 104 + + + - - - -
9032–8 7 2.76 x 104 + + +/- - - - -
9032–9 12 2.81 x 104 + + + - - IND -
9032–10 19 3.72 x 103 + + + + + IND +
9032–11 21 3.42 x 103 + + + + + IND +
9032–12 32 5.94 x 103 + + - + + IND +
9032–13 34 1.03 x 103 + +/- - + + + +
+, reactive test result; -, non-reactive test result; +/-, reactive in 1 of 2 replicates; IND, indeterminate; ND, no data; *, first detectable viral load.
doi:10.1371/journal.pone.0126609.t003
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HIV infection detection using the RT-LAMP assay. In previous studies, we demonstrated the
usefulness of the HIV-1 RT-LAMP assay for detection of both DNA and RNA in a single reac-
tion [16, 17]. In the current study, the primary focus was RNA detection, since high plasma
viral loads are characteristic of acute infection; however, proviral DNAmay also be detected in
whole blood. To enable immediate naked eye visualization of the amplified products, a se-
quence-specific fluorescent detection method was developed for the HIV-1 RT-LAMP assay
[17]. We further modified the detection method by adding the quencher probe directly into the
reaction, which eliminated the need to open the reaction tubes post-amplification. A large
amount of amplicons are produced during the LAMP process and reducing the risk of releasing
these amplicons into the testing environment is crucial for non-laboratory settings. For POC
use, it is advantageous to be able to assess sample positivity immediately post-amplification,
without any additional steps.
Further assay improvements included the design of a novel primer set that recognizes a con-
served region within the HIV-1 integrase sequence. Although assay performance for the RT
and INT primer sets was demonstrated separately for comparison purposes, the primer sets
can be combined in a multiplex RT-LAMP reaction without altering the sensitivity of the reac-
tion [16]. The APTIMA HIV-1 Qualitative Assay and the COBAS AmpliPrep / COBAS Taq-
Man HIV-1 Test V2.0 have both demonstrated that detection of clinical isolates may be
facilitated by targeting two separate, conserved regions within the HIV genome because of the
sequence diversity of HIV-1 [27, 28]. Furthermore, a multiplexed approach may be beneficial
to circumvent potential mismatches due to resistance mutations induced by antiretroviral use.
For POC use, the RT-LAMP assay may be performed using low-tech, portable heating devices,
Fig 2. Summary of HIV-1 Test Results. The figure shows the timing of test positivity in relation to the rapid antibody test (Day 0) for the Zeptometrix cohort.
Each segment of the stacked bar graph represents an individual subject.
doi:10.1371/journal.pone.0126609.g002
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such as the ESEQuant Tube Scanner (Qiagen, Valencia, CA)[29] or non-instrumented nucleic
acid (NINA) heaters [8]. Similar performance between these devices and traditional thermal
cyclers has been demonstrated for the HIV-1 RT-LAMP assay [8]. In the current study, howev-
er, a thermal cycler was used as a matter of convenience for large-scale testing.
Because of the predominant use of rapid tests in non-laboratory settings, a representative
rapid test was used as the primary basis for comparison to the RT-LAMP assay. The antibody-
based Multispot HIV-1/HIV-2 Rapid Test was selected for comparison, given that it is current-
ly used as a supplemental assay in the laboratory testing algorithm. It should be noted, howev-
er, that the Multispot is not currently Clinical Laboratory Improvement Amendments (CLIA)-
waived for use at the POC. In seroconverting individuals, we demonstrated earlier detection
(1–3 weeks) with the RT-LAMP assay as compared to the Multispot HIV-1/HIV-2 Rapid Test.
Since viral RNA is detectable in the plasma up to 4 weeks prior to antibody, depending on the
specific test [30], these results were not unexpected. Furthermore, studies have demonstrated
that the Multispot and other FDA-approved rapid tests show significant weaknesses in detect-
ing early HIV infection [31, 32].
Although the LAMP method is attractive for the development of a rapid POC NAAT, the
HIV-1 RT-LAMP assay may also be useful in select laboratory settings, because of the quicker
turnaround time and lower cost compared to current laboratory NAAT platforms. The HIV-1
RT-LAMP assay is estimated to cost 15-40X less per test compared to APTIMA, depending on
the individual laboratory cost for purchasing the APTIMA kit. In relation to the viral load for
each seroconversion panel member, RT-LAMP exhibited the expected limit of detection for
the assay, which is approximately 104 RNA copies/ mL. Additionally, RT-LAMP had a slight or
no delay in time to detection compared to the current FDA-approved NAAT in the serocon-
verting individuals. The viral loads of all seroconverters included in this study exceeded the
limit of detection for the assay shortly post first RNA-positive test result. Likewise, peak viral
loads during acute HIV infection are estimated to be>100,000 RNA copies/ mL [33].
At present, the fourth-generation is the most sensitive of the laboratory immunoassay plat-
forms, since it detects anti-HIV-1 IgG and IgM antibodies and HIV-1 p24 antigen. Rapid
fourth-generation tests, such as the Determine HIV-1/2 Ag/Ab Combo (Alere, Orlando, FL)
[24, 34, 35], will likely soon be CLIA-waived for use at the POC, but data suggest that it is not
as sensitive for detection of acute infection as laboratory platforms [24, 36–43]. Although p24
antigen narrows the window from infection to detection, nucleic acid remains the earliest de-
tectable biomarker for HIV infection [44]. In support of this, the RT-LAMP assay detected in-
fection up to two weeks earlier than the GS HIV Combo Ag/Ab EIA.
One of the weaknesses of the RT-LAMP assay is that the current format is not as sensitive as
the APTIMA HIV-1 RNA Qualitative Assay, the only FDA-approved NAAT for HIV-1 diag-
nosis. In the current study, the APTIMA detected infection up to five days earlier than the
RT-LAMP assay. This is not surprising given the large discrepancy in input sample volume be-
tween the two assays. When taking into account the extraction process that occurred prior to
adding sample to the reaction, the RT-LAMP assay used only 7% of the sample volume re-
quired for APTIMA. It has been demonstrated that the sensitivity of the RT-LAMP assay can
be increased by increasing the overall reaction volume [16]. In addition, HIV nucleic acids can
be concentrated directly from the clinical specimen through membrane capture/ concentration
methods [18, 45].
Ideally, the HIV-1 RT-LAMP assay would be used with whole blood obtained from a finger
stick. In the current study, we demonstrated the assay performance with plasma samples, given
the difficulty in obtaining well-characterized, longitudinal whole blood samples from recent
seroconverters. Alternatively, commercial seroconversion panels with preexisting HIV testing
data are readily available and can be used to assess the timing of test positivity relative to each
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other. It is not anticipated that the assay results will differ significantly with whole blood, since
the performance of the HIV-1 RT-LAMP assay has been demonstrated in a previous study [8].
Ongoing studies involve the evaluation of single-use, disposable heating devices with lyophi-
lized RT-LAMP reagents for detection of HIV from whole blood specimens. Another limita-
tion of the current study is that the assay was specifically designed for detecting subtype B HIV
infections, since the primary focus of our laboratory is detection of HIV in the US. For global
use, a group M-conserved RT-LAMP assay is preferred. Parallel evaluations of a subtype-con-
served RT-LAMP assay are being performed in our laboratory.
In summary, the availability of a rapid NAAT, such as the HIV-1 RT-LAMP assay, could
improve the diagnosis of acutely infected individuals who might otherwise be missed by cur-
rent rapid antibody tests. The HIV-1 RT-LAMP assay has the potential to be implemented at
the POC, as a supplemental or confirmatory test, where NAAT testing is currently not feasible
due to cost and time limitations.
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